ValuEngine Lowers Kadmon (NYSE:KDMN) to Sell

Kadmon (NYSE:KDMN) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Monday, ValuEngine reports.

Several other research firms have also recently weighed in on KDMN. Zacks Investment Research raised shares of Kadmon from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research note on Wednesday, October 9th. Cantor Fitzgerald started coverage on shares of Kadmon in a research note on Thursday, September 5th. They issued an “overweight” rating and a $8.00 target price for the company. Finally, Oppenheimer started coverage on shares of Kadmon in a research note on Wednesday, June 26th. They issued an “outperform” rating and a $6.00 target price for the company. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Kadmon has an average rating of “Buy” and an average target price of $8.95.

Shares of NYSE:KDMN traded up $0.18 during midday trading on Monday, hitting $3.09. The stock had a trading volume of 589,800 shares, compared to its average volume of 830,042. Kadmon has a 12 month low of $1.63 and a 12 month high of $3.13. The company has a quick ratio of 2.98, a current ratio of 2.99 and a debt-to-equity ratio of 0.45. The business’s 50-day simple moving average is $2.64 and its 200-day simple moving average is $2.38. The company has a market cap of $395.37 million, a P/E ratio of -3.00 and a beta of 2.19.

Kadmon (NYSE:KDMN) last released its earnings results on Monday, August 5th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.03). Kadmon had a negative net margin of 3,974.23% and a negative return on equity of 96.96%. The firm had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.46 million. As a group, equities analysts predict that Kadmon will post -0.54 earnings per share for the current year.

A number of hedge funds have recently added to or reduced their stakes in KDMN. Meeder Asset Management Inc. boosted its position in Kadmon by 736.6% during the third quarter. Meeder Asset Management Inc. now owns 9,955 shares of the company’s stock worth $25,000 after purchasing an additional 8,765 shares during the period. D. E. Shaw & Co. Inc. bought a new position in Kadmon during the second quarter worth $27,000. Parametric Portfolio Associates LLC bought a new position in Kadmon during the second quarter worth $30,000. Capital Investment Advisors LLC boosted its position in Kadmon by 134.5% during the second quarter. Capital Investment Advisors LLC now owns 28,815 shares of the company’s stock worth $59,000 after purchasing an additional 16,525 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in Kadmon by 47.0% during the second quarter. JPMorgan Chase & Co. now owns 35,761 shares of the company’s stock worth $70,000 after purchasing an additional 11,435 shares during the period. 77.02% of the stock is owned by hedge funds and other institutional investors.

Kadmon Company Profile

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.

See Also: What does the Producer Price Index (PPI) tell investors?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.